Trending Up0.1300 (1.6435%)
  • Bid / Lots
    7.1100/ 1
  • Ask / Lots
    9.8500/ 390
  • Open / Previous Close
    7.6400 / 7.9100
  • Day Range
    Low 7.5000
    High 8.3400
  • 52 Week Range
    Low 3.0500
    High 9.9600
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 7.91
09:32 ET57347.85
09:59 ET1007.8
10:06 ET1007.79
10:08 ET2107.7624
10:17 ET1007.765
10:37 ET1007.8
10:42 ET28977.9668
10:51 ET1008
11:04 ET1007.815
11:11 ET1007.9
11:22 ET1007.995
11:33 ET1007.9
11:45 ET11007.97
11:51 ET1037.92
11:54 ET6507.92
12:16 ET1577.94
12:18 ET36018.0358
12:20 ET2008.09
12:27 ET1008.11
12:32 ET2978.13
12:39 ET1008.21
12:41 ET1008.15
12:57 ET4998.18
01:26 ET2008.23
01:42 ET14168.24
01:44 ET32677.9315
01:46 ET10008.005
01:48 ET35647.83
01:51 ET13727.91
02:00 ET1657.83
02:11 ET3007.89
02:13 ET1007.93
02:27 ET10507.94
02:47 ET172367.51
02:49 ET1007.52
02:51 ET5007.605
02:54 ET8797.63
03:03 ET14957.59
03:09 ET3557.66
03:21 ET1007.7225
03:27 ET4787.93
03:34 ET1008.05
03:39 ET1008.04
03:41 ET1228.04
03:43 ET1007.975
03:48 ET1008.06
03:52 ET1008.155
03:56 ET24348.01
03:57 ET8798.01
03:59 ET45728.04
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesXBIT
XBiotech Inc
United StatesPYXS
Pyxis Oncology Inc
United StatesVSTM
Verastem Inc
United StatesINO
Inovio Pharmaceuticals Inc
United StatesCDT
Conduit Pharmaceuticals Inc
United StatesIPSC
Century Therapeutics Inc
As of 2024-04-21

Company Information

XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases, such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. The Company's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The Company is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. It has various candidate products including Natrunix. It has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.

Contact Information

5217 WINNEBAGO LANEAUSTIN, TX, United States 78744


Chairman of the Board, President, Chief Executive Officer, Founder
John Simard
Principal Financial Officer, Director of Finance, Principal Accounting Officer
Angela Hu
Chief Scientific Officer
Sushma Shivaswamy
Lead Independent Director
Jan-Paul Waldin
Independent Director
Peter Libby

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.